Clinical Trial Update: Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating fludarabine and rituximab with or without pixantrone for relapsed/refractory indolent non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Pixantrone (pixantrone)
• Rituximab (rituximab)

Snippet

Sponsor: CTI BioPharma | Conditions: Leukemia, Lymphoma | Phase 3 | Status: WITHDRAWN